Article Text
PDF
Statistics from Altmetric.com
- cerebrovascular disorders
- cholesterol (LDL)
- coronary disease
- drug delivery systems
- heptanoic acids
- pyrroles
Q In patients with stable coronary heart disease (CHD), is intensive atorvastatin therapy more effective than moderate atorvastatin therapy for reducing cerebrovascular events?
Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Neurology ★★★★★★☆ Endocrine ★★★★★★☆
METHODS
Design:
randomised controlled trial.
Allocation:
{concealed*}†.
Blinding:
blinded (clinicians, patients, and endpoints adjudication committee).*
Follow up period:
median 4.9 years.
Setting:
256 sites in 14 countries across 4 continents.
Patients:
10 001 patients 35–75 years of age (mean age 61 y, 81% men) who had clinically evident CHD (defined as previous myocardial infarction or coronary revascularisation, or previous or current angina with objective evidence of CHD), low density lipoprotein cholesterol (LDL-C) concentration 130–250mg/dl (3.4–6.5 mmol/l), and triglyceride concentration ⩽600 mg/dl (6.8 mmol/l). LDL-C concentration was required to be <130 mg/dl (3.4 mmol/l) during an 8 week run in period with atorvastatin, 10 mg/day.
Intervention:
atorvastatin, 80 mg/day (n = 4995) …
Linked Articles
- Other articles noted
- Glossary